2023
DOI: 10.1016/j.actatropica.2023.106846
|View full text |Cite
|
Sign up to set email alerts
|

A review on new natural and synthetic anti-leishmanial chemotherapeutic agents and current perspective of treatment approaches.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(3 citation statements)
references
References 103 publications
0
2
0
Order By: Relevance
“…Others have also shown promising anti-protozoal activities against leishmaniasis [11,12], CD [13,14], and malaria parasites [15,16]. (ACT) as anti-malaria drug [1]; Benznidazole and Nifurtimox for CD treatment [4]; and pentavalent antimonials, Amphotericin B, Paromomycin, and Miltefosine against leishmaniasis [5]. Unfortunately, these therapies are challenged by variable efficiency, severe side effects, long treatment regimens, as well as the development of resistant parasites to the available drugs.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Others have also shown promising anti-protozoal activities against leishmaniasis [11,12], CD [13,14], and malaria parasites [15,16]. (ACT) as anti-malaria drug [1]; Benznidazole and Nifurtimox for CD treatment [4]; and pentavalent antimonials, Amphotericin B, Paromomycin, and Miltefosine against leishmaniasis [5]. Unfortunately, these therapies are challenged by variable efficiency, severe side effects, long treatment regimens, as well as the development of resistant parasites to the available drugs.…”
Section: Introductionmentioning
confidence: 99%
“…Also, more than 1 million cases annually of leishmaniasis have been reported, with 1 billion people living in risk areas. The main current therapies include Artemisinin in the form of combination therapy (ACT) as anti-malaria drug [ 1 ]; Benznidazole and Nifurtimox for CD treatment [ 4 ]; and pentavalent antimonials, Amphotericin B, Paromomycin, and Miltefosine against leishmaniasis [ 5 ]. Unfortunately, these therapies are challenged by variable efficiency, severe side effects, long treatment regimens, as well as the development of resistant parasites to the available drugs.…”
Section: Introductionmentioning
confidence: 99%
“…Currently, the treatment of leishmaniasis relies on first-line drugs such as sodium stibogluconate (commercially known as pentostam) and meglumine antimoniate (commercially known as glucantime), along with alternative options (second-line drugs) such as pentamidine isothionate (commercially known as pentamidine), amphotericin B (Fungizone or ambisome), miltefosine, and paromomycin sulfate (Aminosidine) [6,7]. However, the use of paromomycin sulfate is not widely practiced in several countries due to health regulations, and it does not exhibit effectiveness when administered orally.…”
Section: Introductionmentioning
confidence: 99%